CompanyHealthAi
Retro Biosciences
Retro Biosciences is a clinical-stage longevity biotech in Redwood City, California with a single, unsubtle goal: add ten healthy years to the human lifespan. Founded in 2018 and launched publicly in 2021 with $180 million from OpenAI CEO Sam Altman, the company attacks aging at the cellular level across three platforms - autophagy enhancement, cellular reprogramming, and plasma-inspired therapeutics. Its lead drug, RTR242, an autophagy-restoring small molecule aimed at Alzheimer's disease, entered a first-in-human Phase 1 trial in 2025. A 2026 raise valued Retro at $1.8 billion.
2018Founded
Redwood CityHQ
Undisclosed (valued at $1.8 billion)Later round / valuation update
longevitybiotechagingrejuvenationautophagycellular reprogramming